Gendicine, a recombinant human TP53 adenovirus developed by Shenzhen SiBiono GeneTech Co. Ltd., was approved by the China Food and Drug Administration in 2003 for treating head and neck squamous cell carcinoma. Here, TP53 is linked to head and neck squamous cell carcinoma.